Full text

Turn on search term navigation

Copyright © 2025 Dong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

ABSTRACT

This study evaluates the efficacy of Bifidobacterium longum subsp. longum BL21 in mitigating symptoms of polycystic ovarian syndrome (PCOS) in DHT-induced PCOS model mice. It focuses on BL21’s role in modulating metabolic dysregulation, inflammation, and neuroprotection via the gut–brain–ovary axis. Employing an 8-week treatment regimen, this research assessed the effects of BL21 on prenatal androgen-induced PCOS in ICR mice. Evaluations included body weight, glucose tolerance tests, serum analyses of BDNF, inflammatory markers, sex hormone levels, and 16S rRNA gene sequencing for gut microbiota diversity and composition. Twenty-four ICR mice with induced PCOS served as subjects to examine the probiotic’s impact. Mice were administered a daily oral dose of 1 × 109 CFU of BL21 continuously for a total of 8 weeks. BL21 significantly enhanced sex hormone levels (P < 0.05), particularly those of follicle-stimulating hormone (FSH) and estradiol (E2), indicating improved ovarian function and offering a novel PCOS treatment approach. The intervention notably curbed weight gain and improved glucose tolerance in PCOS mice (P < 0.05). BL21 reduced inflammatory markers such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and lipopolysaccharides (LPS), while increasing IL-10, BDNF, FSH, and E2 levels (P < 0.05 for all). It also enriched gut microbiota diversity, enhancing populations of Bifidobacterium and Lactobacillus. Correlation analyses underscored the positive shifts in microbiota linked to beneficial hormonal and inflammatory profiles. BL21 shows promise in alleviating PCOS symptoms through metabolic regulation, inflammation reduction, and neuroprotection, validating its potential in integrated therapeutic strategies.

IMPORTANCE

Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, characterized by metabolic irregularities, hormonal imbalances, and chronic inflammation. Existing treatments are often inadequate, addressing symptoms without targeting the underlying etiological factors. The investigation of Bifidobacterium longum subsp. longum BL21 as a probiotic intervention offers a novel approach by potentially regulating the gut–brain–ovary axis. This could lead to innovative therapeutic strategies that not only manage but also potentially reverse the multifaceted symptoms of PCOS, enhancing quality of life and reproductive health.

Details

Title
Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut–brain–ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection
Author
Yao, Dong 1   VIAFID ORCID Logo  ; Yang Shengnan 1 ; Zhang, Shu 1 ; Zhao, Yuan 2 ; Li Xinlan 2 ; Han, Mei 3 ; Gai Zhonghui 4 ; Zou, Kang 1   VIAFID ORCID Logo 

 Germline Stem Cells and Microenvironment Lab, College of Animal Science and Technology, Nanjing Agricultural University , Nanjing , China, Stem Cell Research and Translation Center, Nanjing Agricultural University 70578 , Nanjing , China 
 Germline Stem Cells and Microenvironment Lab, College of Animal Science and Technology, Nanjing Agricultural University , Nanjing , China 
 Department of Food Science, Shanghai Business School 127231 , Shanghai , China 
 Department of Research and Development, Wecare Probiotics Co., Ltd. , Suzhou , China 
University/institution
U.S. National Institutes of Health/National Library of Medicine
Publication year
2025
Publication date
2025
Publisher
American Society for Microbiology
e-ISSN
2379-5042
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3203849829
Copyright
Copyright © 2025 Dong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.